Zheng Xing Xing Ye Ri Bao·2025-10-09 09:03Market Overview - On October 9, the medical services sector rose by 0.91%, with Jiuzhou Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Top Gainers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 20.61, up 5.96% with a trading volume of 418,800 shares and a transaction value of 844 million [1] - Meinian Health (002044) closed at 5.20, up 4.63% with a trading volume of 1,667,200 shares and a transaction value of 871 million [1] - Heyuan Biotechnology (688238) closed at 8.20, up 4.19% with a trading volume of 344,500 shares and a transaction value of 285 million [1] - Sanbo Brain Science (301293) closed at 60.80, up 4.02% with a trading volume of 110,100 shares and a transaction value of 660 million [1] - Haoyuan Pharmaceutical (688131) closed at 85.48, up 3.49% with a trading volume of 59,800 shares and a transaction value of 508 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 14.21, down 8.73% with a trading volume of 68,800 shares and a transaction value of 96.92 million [2] - ST Biological (000504) closed at 9.07, down 4.02% with a trading volume of 46,100 shares and a transaction value of 42.42 million [2] - Baicheng Pharmaceutical (301096) closed at 57.99, down 3.35% with a trading volume of 32,600 shares and a transaction value of 191 million [2] Fund Flow Analysis - The medical services sector experienced a net outflow of 308 million from institutional investors, while retail investors saw a net inflow of 348 million [2] - The net outflow from retail investors amounted to 40.85 million [2] Individual Stock Fund Flow - Aier Eye Hospital (300015) had a net inflow of 283 million from institutional investors, while retail investors experienced a net outflow of 137 million [3] - Sanbo Brain Science (301293) saw a net inflow of 63.69 million from institutional investors, with retail investors facing a net outflow of 45.84 million [3] - Jiuzhou Pharmaceutical (603456) had a net inflow of 53.54 million from institutional investors, while retail investors faced a net outflow of 63.40 million [3]